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Original StudieS
Background: Respiratory syncytial virus (RSV) is a major cause of mor-
tality in children younger than 5 years worldwide. Systematic reviews have 
shown that Down syndrome (DS) is an independent risk factor for severe 
RSV infection. We aimed to describe demographic and clinical characteris-
tics of children with DS who died with RSV infection.
Methods: We performed a retrospective case series in which data were 
shared by individual researchers, research networks and physicians world-
wide as part of the RSV Global Online Database study. We included chil-
dren with DS who died when younger than 5 years of age with laboratory-
confirmed RSV infection.
Results: We included 53 children with DS and RSV-related mortality 
from 20 countries in 5 continents. Five (9.4%) children were from low-
income or lower-middle-income countries. Median age at time of death 
was 6.0 months [interquartile range (IQR): 3.00–12.0]. Thirteen (24.5%) 
children were born term and had no other risk factors for severe RSV dis-
ease. In total, 36 (67.9%) children had congenital heart disease, 8 (15.1%) 
had chronic lung disease and 1 (1.9%) had congenital immunodeficiency. 
Duration of hospitalization was significantly longer for children with DS 
compared with children without DS [median length of stay, 13 days (IQR: 
6.8–21.0) vs. 8 days (IQR: 3.0–18.5), P=0.005].
Conclusions: One-fourth of children with DS and RSV-confirmed death 
did not have risk factors for severe RSV disease, indicating that DS is an 
important risk factor for RSV-related mortality. Age distribution at time of 
death demonstrates that maternal vaccination would not be sufficient to pro-
tect children with DS against RSV-related mortality.
Key Words: Down syndrome, respiratory syncytial virus, acute respiratory 
tract infection, mortality
(Pediatr Infect Dis J 2020;39:665–670)
Respiratory syncytial virus (RSV) is one of the leading patho-gens causing lower respiratory tract infections (LRTIs) in 
infants and young children and is a major cause of mortality in 
children younger than 5 years of age worldwide.1–3 Well-known risk 
factors for severe RSV disease are prematurity, congenital heart 
disease (CHD) and chronic lung disease. In addition, our Dutch 
birth cohort comprising 395 children revealed that Down syndrome 
(DS) is an independent risk factor of severe RSV-associated LRTIs.4 
This was subsequently confirmed in several other studies5–8 includ-
ing the Danish national birth registry.9 Because DS is one of the 
most common genetic birth defects with a worldwide incidence of 
1 in 800–1000 live births annually,10,11 strategies that prevent severe 
RSV disease in this high-risk group could have global impact on 
RSV-related mortality.
Currently, the only available strategy to protect children at 
risk against RSV infection is passive immunization by RSV-spe-
cific monoclonal antibodies (palivizumab). Other potential future 
strategies include infant and pediatric vaccination and passive 
immunization by maternal vaccination or by extended half-life 
antibodies.12 Several vaccine candidates are under clinical devel-
opment,13 and a recent phase III maternal vaccine trial has shown 
promising results.14,15
To guide policy makers on the implementation of perinatal 
immunization strategies, the efficacy of these strategies for the dif-
ferent target populations needs to be investigated. For this, informa-
tion on age distribution and clinical manifestations of RSV-related 
mortality is of major importance.16,17 Data on global RSV-related 
mortality in children with DS are absent. The aim of this study 
was to describe demographic and clinical characteristics of chil-
dren with DS who died in hospital with RSV-confirmed infection 
younger than 5 years of age.
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MATERIALS AND METHODS
Study Design and Study Population
We performed a retrospective study involving a subgroup 
of children with DS derived from the RSV Global Online Database 
(GOLD). In short, RSV GOLD is an ongoing global study that ret-
rospectively analyzes individual data of children who died with RSV 
infection. Collaborators can share cases through a link to an online 
questionnaire in Research Online, an electronic data capture platform.18 
Each case is validated with the collaborator by RSV GOLD team 
members to ensure data quality. Detailed description of data collection 
and validation and primary results have already been published.3 The 
initial results (GOLD I) included data from January 1, 1995, to Octo-
ber 31, 2015. The study was extended (GOLD II) and includes data 
from nosocomial infections as well as community-acquired infections 
up to 2020. For the current study, we analyzed cases of children with 
DS from GOLD I (n = 17) and new cases (GOLD II, n = 36).
Data Collection and Case Definition
Included were children with DS who died younger than 5 years 
of age with laboratory-confirmed RSV infection. Mortality cases 
that occurred before 1995 were excluded. We extracted the following 
demographic characteristics: gender, gestational age in weeks, prema-
turity and country of origin. Prematurity was defined as gestational 
age <37 weeks. Country of origin was categorized as low-income, 
lower-middle-income, upper-middle-income, and high-income based 
on the World Bank classifications for 2020.19 Clinical characteristics 
consisted of presenting signs and symptoms, length of stay in hospital, 
admission to an intensive care unit (ICU), ICU length of stay, the need 
for mechanical ventilation and the presence of comorbidities. The fol-
lowing comorbidities were distinguished: CHD, chronic lung disease, 
pulmonary hypertension, congenital hypothyroidism, immune disor-
der, neuromuscular disorder and cancer. When data for comorbidities 
or prematurity were not recorded, we performed data validation and 
inquired with the collaborators whether this information was available. 
If this was not the case, we assumed that the children were born term 
and had no comorbidities besides DS. We compared demographic and 
clinical characteristics of children with DS with and without comor-
bidities. We also compared characteristics of children with DS from 
GOLD I and II to children without DS from GOLD I.
Age Distribution at Time of Death
RSV GOLD was initiated to inform the maternal vaccine 
program. A maternal vaccine will provide only temporary protection 
of approximately 3 months after birth due to the gradual decline of 
maternally derived antibodies.20 Therefore, we determined the pro-
portion of children who died within the first 3 months after birth that 
could have been potentially prevented by a maternal vaccine. We 
distinguished additional risk factors for severe RSV disease, consist-
ing of prematurity and the following comorbidities: CHD, chronic 
lung disease, immune disorder and cancer. Age distribution at time 
of death was compared between children with DS and additional fac-
tors for severe RSV disease and children with DS without additional 
risk factors. We performed a sensitivity analysis excluding cases with 
missing data for prematurity. Furthermore, we compared the age dis-
tribution at time of death between children with DS and without DS.
Statistical Analysis
Continuous variables are presented as the median with 
interquartile ranges (IQRs). Categorical variables are presented as 
numbers and percentages. A χ2 test or Fisher exact test was used to 
determine statistical significance between groups in case of dichot-
omous parameters. A Mann-Whitney U test was used for all con-
tinuous data, assuming a non-normal distribution. A P value <0.05 
was considered statistically significant. SPSS (version 21.0; IBM 
Corp, Armonk, NY) was used for all analyses.
Ethics Statement
Because this is a retrospective study in which only anonymized 
secondary patient data were involved, parental informed consent 
was not deemed necessary by the institutional research board of the 
University Medical Centre Utrecht. Ethics approval was obtained 
for a few individual collaborating institutes when needed.
RESULTS
Fifty-three children with DS who died younger than 5 
years of age with laboratory-confirmed severe RSV infection were 
reported to the RSV GOLD registry between January 1, 1995, and 
June 21, 2019 (Fig. 1). The majority of cases occurred after 2010; 
median year of death was 2012.
Demographic and Clinical Characteristics
Reported children originated from 20 different countries 
across the world (Table, Supplemental Digital Content 1, http://
links.lww.com/INF/D890; Figure, Supplemental Digital Content 
2, http://links.lww.com/INF/D891. Five (9.4%) children were from 
low-income or lower-middle-income countries, 27 (50.9%) children 
were from upper-middle-income countries and 22 (41.5%) children 
were from high-income countries. Median reported gestational age 
was 37 weeks (IQR: 35.8–38.2). Thirteen (24.5%) children were 
born prematurely (data on prematurity were missing for 14/53 chil-
dren). The majority of children with DS were male (n = 31, 58.5%). 
Main presenting signs and symptoms were difficulty with breathing 
(n = 35/46, 76.1%) and coughing (n = 27/43, 62.8%). Median 
length of hospital stay was 13 days (IQR: 6.8–21.0). Forty 
(n = 40/48, 83.3%) children were admitted to an ICU, and 33 
FIGURE 1. Inclusion of children with Down syndrome from 
the RSV GOLD I and II registry.
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(n = 33/51, 64.7%) children required mechanical ventilation for a 
median duration of 10 days (IQR: 6.0–16.0). Median age at time of 
RSV-related death was 6 months (IQR: 3.0–12.0). Comorbidities 
were reported for 39 (73.6%) children with DS. Nine children had 
more than 1 comorbidity (Table 1). Seven children had a confirmed 
nosocomial RSV infection. Data on administration of palivizumab 
were available for 13 children. Of these, only 1 child with DS and 
nonhemodynamically significant CHD had received palivizumab 
prophylaxis, consisting of 1 dose at the beginning of the RSV season. 
The child died at the end of the RSV season at the age of 5 months.
Proportion of RSV-related Deaths 3 Months of age 
or Younger
Thirty-eight (71.7%) children were younger than 12 months 
at time of RSV-related death and 10 (18.9% of total) of these chil-
dren were younger than 3 months at time of death. The distribu-
tions for gestational age and age at RSV-related death in children 
with DS younger than 12 months are shown in Figure 2. The dis-
tributions for gestational age and age at RSV-related death in all 
reported children with DS are shown in Figure, Supplemental Digi-
tal Content 3, http://links.lww.com/INF/D892.
Comparison Between Children With DS With and 
Without Risk Factors for Severe RSV Disease
In total, 13 (24.5%) children were born term and had no 
risk factors for severe RSV disease other than DS. We compared 
age distribution at time of RSV-related death between children with 
DS younger than 12 months with (n = 28) and without (n = 10) 
additional risk factors for severe RSV disease (Fig. 3) and for all 
reported cases (Figure, Supplemental Digital Content 4, http://links.
lww.com/INF/D893. There was no significant difference in age at time 
of death between groups (P = 0.74 and P = 0.56, respectively). A sen-
sitivity analysis excluding cases with missing data for gestational age 
and no additional risk factors (n = 5) gave a similar result (P = 0.59).
Comparison Between Children With and  
Without DS
In Table, Supplemental Digital Content 5, http://links.lww.
com/INF/D894, we compared characteristics of children with DS 
and without DS (GOLD I, previously published).3 Children with DS 
had significantly less presenting signs and symptoms of respiratory 
tract infection (P < 0.0005) but were hospitalized longer [median 
length of stay, 13 days (IQR: 6.8–21.0) vs. 8 days (IQR: 3.0–18.5), 
P = 0.005]. This difference was still significant (P = 0.02) when 
excluding children with confirmed nosocomial infection [median 
length of stay, 12 days (IQR: 6.0–20.0)]. There was no statistical 
difference in age at time of death between groups (P = 0.64, Figure, 
Supplemental Digital Content 6, http://links.lww.com/INF/D895), 
also when excluding children with confirmed nosocomial infection. 
We subsequently analyzed children with and without DS, without 
additional risk factors for severe RSV disease (Figure, Supplemen-
tal Digital Content 7, http://links.lww.com/INF/D896). Again, there 
was no statistically significant difference in age at time of death 
between groups (P = 0.95).
TABLE 1. Demographic Characteristics, Clinical Characteristics and Comorbidity Status of Children With Down 
Syndrome Under 5 Years of Age Who Died With Laboratory-Confirmed RSV Infection
All Cases (N = 53) Comorbidities (N = 39) No Comorbidities (N = 14) P Value
Demographic characteristics     
  Male gender, N/T (%) 31/53 (58.5) 18/39 (46.2) 4/14 (28.6) 0.35
  Gestational age in weeks, median (IQR); N 37.0 (35.8–38.2); 22 37.0 (35.5–38.4); 17 37.0 (34.0–39.0); 5 0.87
  Prematurity, N (%)* 13 (24.5) 11 (28.2) 2 (14.3) 0.47
  Country of origin     
   Low-income, N/T (%) 2/53 (3.8) 1/39 (2.6) 1/14 (7.1) 0.46
    Lower-middle-income, N/T (%) 3/53 (5.7) 1/39 (2.6) 2/14 (14.3) 0.17
    Upper-middle-income, N/T (%) 27/53 (50.9) 23/39 (59.0) 4/14 (28.6) 0.07
   High-income, N/T (%) 21/53 (39.6) 14/39 (35.9) 7/14 (50.0) 0.36
Clinical characteristics     
  Presenting signs and symptoms     
   Difficulty with breathing, N/T (%) 35/46 (76.1) 26/32 (81.3) 9/14 (64.3) 0.27
   Coughing, N/T (%) 27/43 (62.8) 20/30 (66.7) 7/13 (53.8) 0.50
   Fast breathing, N/T (%) 26/44 (59.1) 18/30 (60.0) 8/14 (57.1) 0.86
   Chest indrawing, N/T (%) 16/46 (34.8) 14/32 (43.8) 2/14 (14.3) 0.09
   Fever, N/T (%) 20/52 (38.5) 15/38 (39.5) 5/14 (35.7) 0.81
   Severe respiratory distress†, N/T (%) 10/41 (24.4) 6/28 (21.4) 4/13 (30.8) 0.70
   Inability to drink, N/T (%) 6/38 (15.8) 5/25 (20.0) 1/13 (7.7) 0.64
   Central cyanosis, N/T (%) 8/41 (19.5) 7/28 (25.0) 1/13 (7.7) 0.40
  Length of stay in hospital in days, median (IQR); N 13.0 (6.8–21.0); 50 12.0 (7.0–21.0); 39 14.0 (3.0–21.0); 11 0.80
  ICU admission, N/T (%) 40/48 (83.3) 32/38 (84.2)‡ 8/11 (72.7)‡ 0.22
  ICU length of stay in days, median (IQR); N 11.0 (6.0–16.3); 28 11 (6.0–18.0); 25 12.0 (3.0–N/A); 3 0.74
  Mechanical ventilation, N/T (%) 33/51 (64.7) 28/37 (75.7) 5/14 (35.7) 0.02
  Duration of mechanical ventilation in days, median 
(IQR); N
10.0 (6.0–16.0); 27 10.0 (6.25–16.75); 24 12.0 (3.0–N/A); 3 0.64
  Age at time of death in months, median (IQR); N 6.0 (3.0–12.0); 53 6.0 (3.0–12.0); 39 6.5 (2.0–13.25); 14 0.77
Comorbidity status*     
  Congenital heart disease, N (%) 36 (67.9) 36 (92.3) N/A N/A
  Chronic lung disease, N (%) 8 (15.1) 8 (20.5) N/A N/A
  Immunodeficiency, N (%) 1 (1.9) 1 (2.6) N/A N/A
  Neuromuscular disorder, N (%) 2 (3.8) 2 (5.1) N/A N/A
  Other¶ 4 (7.5) 4 (10.3) N/A N/A
*Considered absent when missing.
†Grunting, very severe chest indrawing.
‡For 1 case from Mali, there was no ICU available.
¶Congenital hypothyroidism (N = 1), cancer (N = 2) and pulmonary hypertension (N = 1).
N indicates number; N/A, not available; T, total.
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DISCUSSION
This study is the first global case series of children with DS 
who died with RSV-confirmed infection. We evaluated the demo-
graphic and clinical characteristics of these children and found that 
median age at death was 6 months. Median age at death was similar 
in children with and without risk factors other than DS for severe 
RSV disease and similar in children with and without DS.
This study adds to the existing literature by describing 
demographic and clinical characteristics from 53 children with DS 
from 20 different countries. LRTIs are the primary cause of hos-
pitalization21 and form a major cause of mortality in children with 
DS.22 We have previously shown that DS is an independent risk 
factor for severe RSV infection,4 and this was confirmed by oth-
ers.5–9 In 3 meta-analyses, the relative risk for RSV hospitalization 
for children with DS was found to be 6- to 8-fold higher compared 
with children without DS,6,22,23 and the relative risk of mortality 
was approximately 9-fold higher for children with DS.22 Increased 
susceptibility for severe LRTIs in this group may be explained by 
3 factors: first, DS-associated airway malformations, such as laryn-
gotracheomalacia, alveolar and pulmonary hypoplasia24,25; second, 
DS-associated comorbidities, such as hemodynamically significant 
CHD, pulmonary hypertension, generalized hypotonia, swallowing 
dysfunction with increased risk of aspiration; and third, immuno-
logic impairments, such as decreased NK-cell activity, abnormal 
thymus function, lower numbers of T and B cells and decreased 
T-cell proliferation and cytotoxicity.26,27 Altogether, these factors 
accumulate to an increased risk of death in case of RSV infection.
When comparing children with DS to children without DS, 
we found that children with DS were hospitalized longer than chil-
dren without DS. A possible explanation could be that physicians 
may tend to admit children with DS and respiratory tract infection 
(RTI) quicker than other children with RTI due to the presence of 
the above-mentioned risk factors for severe respiratory disease.
Prevention of RSV-related morbidity and mortality is needed 
for children with DS. To date, the only available RSV prophylaxis 
is palivizumab, a humanized monoclonal antibody which is admin-
istered monthly before the start of the RSV season.28 The efficacy 
of palivizumab is firmly established29,30 and routinely recommended 
for children with CHD, chronic lung disease or born prematurely. 
Some pediatricians advocate offering palivizumab to every child 
with DS up to 2 years of age,31,32 while others await the develop-
ment of an RSV vaccine. Currently, most prophylaxis guidelines do 
not yet recommend palivizumab for children with DS33,34 because 
there are insufficient studies that address the efficacy and cost-effec-
tiveness of palivizumab in children with DS without additional risk 
factors for severe RSV disease.35 The American Academy of Pedi-
atrics states that children with DS without additional risk factors 
are generally older at RSV-related hospitalization compared with 
children with additional risk factors (median age, 9 vs. 4 months).36 
Therefore, immunoprophylaxis for the first year of life would be of 
limited effect.33 On the other hand, some countries have included DS 
as possible indication for palivizumab prophylaxis in their guide-
lines, acknowledging that randomized controlled trials are challeng-
ing to conduct due to the projected large sample size and ethical 
concerns.37 Nevertheless, palivizumab is costly and therefore barely 
available in low-income and lower-middle-income countries.
The results of the first maternal RSV vaccine candidate reach-
ing phase 3 showed prevention of severe RSV infection in babies 
born to vaccinated mothers, but the trial did not meet its primary end-
point.14 In the present study, approximately one-fifth of cases were 
younger than 3 months at time of death. This implies that maternal 
vaccination may not sufficiently protect all children with DS against 
life-threatening RSV infection, given the fact that the level of mater-
nally acquired RSV-specific antibodies declines over time after birth 
and will only provide temporary protection.17,38,39 As an alternative 
to palivizumab, which requires multiple dosing during the RSV sea-
son and is therefore costly, an extended half-life monoclonal anti-
body has been developed (nirsevimab, previously MEDI8897). This 
highly potent antibody has shown promising results in a phase IIb 
trial and was recently granted Breakthrough Therapy Designation by 
the United States Food and Drug Administration.40
The strengths of this study consist of the global representa-
tion of RSV-related mortality in children with DS in our mortality 
registry. Large studies such as RSV GOLD are essential to obtain 
sufficient global data for this high-risk group. We have obtained 
FIGURE 2. Distribution of 
gestational age (GA) (N = 34*) 
and age in weeks at time of 
RSV-related death for children 
with Down syndrome <12 
months (N = 38). *Four cases 
were excluded because they 
were born prematurely with 
unknown GA.
FIGURE 3. Distribution of age in weeks at time of RSV-
related death for children with Down syndrome with (N = 28) 
and without (N = 10) additional risk factors for severe RSV 
disease <12 months.
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good data quality by verifying each case directly with the RSV 
GOLD collaborators. Furthermore, we differentiated between chil-
dren with DS with and without comorbidities and risk factors for 
severe RSV disease.
There are also limitations to this study. First, only 53 children 
with DS were reported to the RSV GOLD registry. This is a small 
proportion of all children with DS who died with RSV worldwide. 
We could not estimate the actual burden of RSV-related death in this 
high-risk group because the incidence of DS was not available for 
most countries. In addition, not all RSV-related mortality cases that 
occurred in these countries have been shared with the GOLD regis-
try. However, we believe that children with DS are overrepresented 
in the RSV GOLD mortality registry, because the proportion of chil-
dren with DS reported to the registry is larger than the prevalence 
of DS in the general population (1:19 reported GOLD cases vs. 
1:1200 in the population41). Second, because we collected data from 
20 different countries over a period of more than 25 years, quality 
of care might have differed substantially between cases. Third, data 
for prematurity and (severity of) comorbidities were often incom-
plete, such as type of CHD and whether the child underwent car-
diac surgery before RSV infection. This could have resulted in an 
underestimation of the proportion of children with DS with addi-
tional comorbidities and children who were born prematurely. How-
ever, the estimated general incidence of CHD in children with DS is 
comparable to our results (50%–66.6%42,43 vs. 67.9%, respectively). 
Furthermore, since DS was already reported for these children, it 
is more likely that other comorbidities, if present, would also have 
been reported. Moreover, a sensitivity analysis excluding cases with 
missing data for gestational age gave similar results. Fourth, because 
nosocomial RSV infection and stem cell transplantation were exclu-
sion criteria for GOLD I, the proportion of children with nosocomial 
RSV infections and of those who received stem cell transplantation 
is underrepresented in this study. Lastly, this study hardly represents 
children with DS from low-income and lower-middle-income coun-
tries. This is most likely due to a lack of RSV testing and to lim-
ited access to healthcare—leading to both early death in children 
with DS with underlying comorbidities before they become RSV 
infected and to RSV-related death in the community.
In conclusion, children with DS are at increased risk of RSV-
related death and need adequate protection against RSV infection. 
Considering median age at death, maternal vaccination will not be 
sufficient for this high-risk group.
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